Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Prolactinoma
NEJM 349:2035-2041, Schlechte,J.A., 2003
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
NEJM 349:2023-2033, Colao,A.,et al, 2003
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Management of Pituitary Tumors
Ann Int Med 129:472-483, Shimon,I.&Melmed,S., 1998
Chiasmal Herniation as a Complication of Bromocriptine Therapy
J Neuro-Ophthalmol 16:252-257, Taxel,P.,et al, 1996
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Prolactin-Secreting Macroadenomas in Adolescents, Response to Bromocriptine Therapy
Am J Dis Child 147:1057-1061, Tyson,D.,et al, 1993
Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993
Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Treatment of Prolactin-Secreting Pituitary Macroadenomas with the Long-Acting Non-Ergot Dopamine Agonist CV 205-502
Ann Int Med 112:668-673, Vance,M.L.,et al, 1990
Acromegaly
NEJM 322:966-977, Melmed,S., 1990
Hyperprolactinaemia, Common and Treatable
BMJ 297:701-702, Hartog,M.&Hull,M.G.R., 1988
Dopamine Agonists, In Parkinson's Disease and Movement Disorders
Urban & Schwarzenberg, Balt, p. 104., Jankovic,J.&Tolosa,E., 1988
Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986
Prolactinomas
Editorial, BMJ 290:182-1841985., Grossman,A.,et al, 1985
Low Doses of Dopamine Agonists in the Long-Term Treatment of Macroprolactinomas
NEJM 313:656-659, Liuzzi,A.,et al, 1985
Psychotic Reactions During Treatment of Pituitary Tumours with Dopamine Agonists
BMJ 289:1101-1103, Turner,T.H.,et al, 1984
Effect of Dopamine Agonist Withdrawal After Long-Term Therapy in Prolactinomas
Lancet 2:187-192, Johnston,D.G.,et al, 1984
Reduction in Size of Prolactin-secreting Tumours in Men Treated with Pergolide
BMJ 285:465-467, Kendall-Taylor,P.,et al, 1982
Treatment of Advanced Parkinson Disease With Pergolide
Neurol 31:675-682, Lieberman,A.,et al, 1981
The Prolactinoma Problem
NEJM 300:313-315, Reichlin,S., 1979
Drug Therapy, Bromocriptine
NEJM 301:873-878, Parkes,D., 1979
Prolactin-Secreting Tumors & Hypogonadism in 22 Men
NEJM 299:847-852, Carter,J.N.,et al, 1978